SCHEDULE: Armistice Capital Takes 9.79% Stake in Citius Oncology
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd report a 9.79% beneficial ownership stake in Citius Oncology, Inc. common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 7,675,911 shares of Citius Oncology, Inc. common stock.
- This ownership represents 9.79% of the total class of securities outstanding.
- The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- The percentage of shares is based on 78,370,584 shares outstanding as of August 11, 2025, as reported in Citius Oncology's 10-Q filed on August 12, 2025.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual report of beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Citius Oncology, a company operating in the oncology sector. Such a substantial stake by an investment manager like Armistice Capital can signal investor confidence in the company's future prospects or strategic direction within the competitive biotechnology and pharmaceutical industry.
Related Party Transactions
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the Citius Oncology shares. Steven Boyd is the managing member of Armistice Capital, LLC. This structure defines the beneficial ownership relationship.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.79% stake by an institutional investor like Armistice Capital may be viewed as a vote of confidence, potentially influencing market perception and share price. It also introduces a large, potentially influential, shareholder into the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Date as of which 78,370,584 shares of Citius Oncology, Inc. were outstanding, as reported in the Issuer's 10-Q. |
| 08/12/2025 | Date Citius Oncology, Inc. filed its 10-Q with the SEC, reporting shares outstanding. |
| 09/30/2025 | Date of event which requires the filing of this statement. |
| 11/14/2025 | Date the Schedule 13G statement was signed by Armistice Capital, LLC and Steven Boyd. |
Keywords
Citius Oncology, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.